Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (NDAQ:AZN)

PathAI to Present Machine Learning-based Quality Control Tool for HER2 Testing in Breast Cancer at the American Society of Clinical Oncology Virtual Scientific Program 2021

PR Newswire June 8, 2021

CALQUENCE Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia and Sustained Patient Benefit at Four Years in the Front-line Setting

Business Wire June 7, 2021

IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years

Business Wire June 4, 2021

LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial

Business Wire June 3, 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

GlobeNewswire May 20, 2021

AstraZeneca ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience

Business Wire May 19, 2021

New FASENRA® Data From the MELTEMI Extension Trial Confirm Long-Term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years

Business Wire May 19, 2021

Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA

PR Newswire May 10, 2021

IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer

Business Wire May 7, 2021

FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes

Business Wire April 30, 2021

ENHERTU® ? (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER

Business Wire April 20, 2021

AstraZeneca Announces Collaboration with Massachusetts General Hospital to Accelerate Digital Health Solutions

Business Wire April 6, 2021

AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation - AZN

PR Newswire March 31, 2021

Futures Fall as Tech Shares Target

Livemoney March 30, 2021

DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile March 29, 2021

AZN Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important March 29 Deadline in Securities Class Action - AZN

Newsfile March 29, 2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA March 29, 2021

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm

GlobeNewswire March 26, 2021

AstraZeneca Shareholder Alert

Newsfile March 26, 2021

FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important March 29 Deadline in Securities Class Action - AZN

ACCESSWIRE IA March 26, 2021